Status:
UNKNOWN
Multi-CAR-T Cells Targeting B Cell Lymphomas
Lead Sponsor:
Shenzhen Geno-Immune Medical Institute
Collaborating Sponsors:
The Seventh Affiliated Hospital of Sun Yat-sen University
Shenzhen Children's Hospital
Conditions:
B Cell Lymphoma (BCL)
Eligibility:
All Genders
6-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CAR...
Detailed Description
Chimeric antigen receptor (CAR) T cell therapy has proven effective in treating B cell malignancies. However, post CD19-CART relapses occur at high rate due to the CD19 antigen loss or the exhaustion ...
Eligibility Criteria
Inclusion
- Age older than 6 months.
- Primary B cell lymphoma surface expression of CD19 and/or CD22/CD70/PSMA/ CD13/CD79b/GD2 molecules.
- The KPS score over 80 points, and survival time is more than 1 month.
- Greater than Hgb 80 g/L.
- No contraindications to blood cell collection.
Exclusion
- Accompanied with other active diseases, and difficult to assess response after treatment.
- Bacterial, fungal, or viral infection, unable to control.
- Living with HIV.
- Active HBV and HCV infection.
- Pregnant and nursing mothers.6. under systemic steroid treatment within a week of the treatment.
- 7\. Prior failed CAR-T treatment.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04429438
Start Date
June 1 2020
End Date
December 31 2023
Last Update
June 12 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen Children's Hospital
Shenzhen, Guangdong, China, 518000
2
Shenzhen Geno-Immune Medical Institute
Shenzhen, Guangdong, China, 518000
3
The Seventh Affilliated Hospital, Sun Yat-Sen University
Shenzhen, Guangdong, China, 518107